Challenges in clinical patient management

Cancer Investigation

Volumn 28, Issue SUPPL. 1, 2010, Pages 14-27

  Aapro, Matti S ^a  

^a CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

adjuvant hormonal therapy; current practice; early stage breast cancer; management

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANASTROZOLE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CLONIDINE; CYCLOOXYGENASE 2 INHIBITOR; DENOSUMAB; EXEMESTANE; GABAPENTIN; GOSERELIN; IBANDRONIC ACID; LETROZOLE; MEDROXYPROGESTERONE; MEGESTROL ACETATE; NAPROXEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PARACETAMOL; PAROXETINE; PLACEBO; PRASTERONE; RISEDRONIC ACID; TAMOXIFEN; VENLAFAXINE; VITAMIN D; ZOLEDRONIC ACID;

ARTHRALGIA; BONE ATROPHY; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ESTROGEN SYNTHESIS; FOLLOW UP; FRACTURE; FRAGILITY FRACTURE; GROUPS BY AGE; HOT FLUSH; HUMAN; LYMPH NODE METASTASIS; MENOPAUSE; MICROMETASTASIS; MOLECULARLY TARGETED THERAPY; NIGHT SWEAT; OSTEOPOROSIS; PATIENT CARE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVIEW; THROMBOEMBOLISM; VISCERAL METASTASIS;

AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HUMANS; MEDICATION ADHERENCE; OSTEOPOROSIS; TAMOXIFEN;

EID: 77954978442     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.501648     Document Type: Review

References (137)

1. Perez, E.A. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 2007, 18(Suppl 8), viii26-viii35.
2. Abdulhaq, H.; Geyer, C. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer. Am J Clin Oncol 2008, 31(6), 595-605.
3. Hadji, P. Menopausal symptoms and adjuvant therapyassociated adverse events. Endocr Relat Cancer 2008, 15(1), 73-90.
4. Jordan, V.C.; Allen, K.E.; Dix, C.J. Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 1980, 64(6-7), 745-749.
5. Cuzick, J.; Wale, C., on behalf of the ATAC Trialists' Group. A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years treatment. Breast Can Res Treat 2006, 100(Suppl 1), S24. Abstract 104.
6. Duffy, S. Anastrozole is associated with a lower risk of endometrial abnormalities than tamoxifen: first report of the ATAC trial endometrial sub-protocol at 6 years' follow-up. Breast Cancer Res Treat 2006, 106(Suppl 1), S145. Abstract 4055.
7. Ozair, S.; Iqbal, S. Efficacy and safety of aromatase inhibitors in early breast cancer. Expert Opin Drug Saf 2008, 7(5), 547-558.
8. Miller, W.R.; Bartlett, J.; Brodie, A.M.H.; Breuggemeier, R.W.; Di Salle, E.; Lonning, P.E.; Llombart, A.; Maass, N.; Maudelonde, T.; Sasano, H.; Goss, P.E. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008, 13(8), 829-837.
9. Fabian, C.J. The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Int J Clin Pract 2007, 61(12), 2051-2063.
10. Macedo, L.F.; Sabnis, G.; Brodie, A. Aromatase inhibitors and breast cancer. Ann N Y Acad Sci 2009, 1155(Feb), 162-173.
11. Geisler, J. Aromatase inhibitors: from bench to bedside and back. Breast Cancer 2008, 15(1), 17-26.
12. Geisler, J.; King, N.; Dowsett, M.; Ottestad, L.; Lundgren, S.; Walton, P.; Kormeset, P.O.; Lønning, P.E. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996, 74(8), 1286-1291.
13. Geisler, J.; King, N.; Anker, G.; Ornati, G.; Di Salle, E.; Lønning, P.E.; Dowsett, M. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998, 4(9), 2089-2093.
14. Geisler, J.; Haynes, B.; Anker, G.; Dowsett, M.; Lonning, P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002, 20, 751-757.
15. Dowsett, M.; Jones, A.; Johnston, S.R.; Jacobs, S.; Trunet, P.; Smith, I.E. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995, 1(12), 1511-1515.
16. Miller, W.R. Aromatase inhibitors - where are we now? Br J Cancer 1996, 73(4), 415-417.
17. Lønning, P.E. Pharmacology of new aromatase inhibitors. Breast 1996, 5(3), 202-208.
18. Dixon, J.M.; Renshaw, L.; Young, O.; Murray, J.; Macaskill, E.J.; McHugh, M.; Folkerd, E.; Cameron, D.A.; A'Hern, R.P.; Dowsett, M. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 2008, 26(10), 1671-1676.
19. Thürlimann, B.; Keshaviah, A.; Coates, A.S.; Mouridsen, H.; Mauriac, L.; Forbes, J.F.; Paridaens, R.; Castiglione-Gertsch, M.; Gelber, R.D.; Rabaglio, M.; Smith, I.; Wardley, A.; Price, K.N.; Goldhirsch, A.; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl JMed 2005, 353(26), 2747-2757. (Pubitemid 43016814)
20. Mouridsen, H.; Giobbie-Hurder, A.; Goldhirsch, A.; Thürlimann, B.; Paridaens, R.; Smith, I.; Mauriac, L.; Forbes, J.F.; Price, K.N.; Regan, M.M.; Gelber, R.D.; Coates AS; BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361(8), 766-776.
21. Monnier, A. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial. Expert Rev Anticancer Ther 2007, 6(10), 1355-1359.
22. Moy, B.; Elliott, C.R.; Chapman, J-AW; Pater, J.L.; Ding, Z.; Goss, P.E. NCIC CTG MA.27: menopausal symptoms of ethnic minority women. Breast Cancer Res Treat 2006, 100(Suppl 1), S144. Abstract 3059.
23. Berry, J. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Clin Ther 2005, 27(11), 1671-1684.
24. Howell, A.; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M.; Forbes, J.F.; Hoctin-Boes, G.; Houghton, J.; Locker, G.Y.; Tobias JS; ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365(9453), 60-62.
25. Coombes, R.C.; Kilburn, L.S.; Snowdon, C.F., et al; Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007, 369(9561), 559-570.
26. Coates, A.S.; Keshaviah, A.; Thürlimann, B.; Mouridsen, H.; Mauriac, L.; Forbes, J.F.; Paridaens, R.; Castiglione-Gertsch, M.; Gelber, R.D.; Colleoni,M.; Ĺang, I.; Del Mastro, L.; Smith, I.; Chirgwin, J.; Nogaret, J.M.; Pienkowski, T.; Wardley, A.; Jakobsen, E.H.; Price, K.N.; Goldhirsch, A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007, 25(5), 486-492.
27. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Forbes, J.F.; Cuzick, J.; Buzdar, A.; Howell, A.; Tobias, J.S.; Baum, M. Lancet Oncol. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9(1), 45-53.
28. Coombes, R.C.; Hall, E.; Gibson, L.J.; Paridaens, R.; Jassem, J.; Delozier, T.; Jones, S.E.; Alvarez, I.; Bertelli, G.; Ortmann, O.; Coates, A.S.; Bajetta, E.; Dodwell, D.; Coleman, R.E.; Fallowfield, L.J.; Mickiewicz, E.; Andersen, J.; Lønning, P.E.; Cocconi, G.; Stewart, A.; Stuart, N.; Snowdon, C.F.; Carpentieri,M.; Massimini, G.; Bliss, J.M.; van de Velde, C.; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350(11), 1081-1092. Erratum in: N Engl J Med 2004, 351(23):2461. (Pubitemid 38298988)
29. Presant, C.; Kelly, C.; Bosserman, L.; Upadhyaya, G.; Vakil, M.; Horns, R.; Ebrahimi, B.; Yeon, C.; Howard, F.; Rios, A. Aromatase inhibitor (AI)-associated arthralgia (A) and bone pain (BP): frequency and characterization in clinical practice. J Clin Oncol 2006, 24, 334s. Abstract 6137.
30. Saad, F.; Adachi, J.D.; Brown, J.P.; Canning, L.A.; Gelmon, K.A.; Josse, R.G.; Pritchard, K.I. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008, 26(33), 5465-5476.
31. Chaiamnuay, S.; Saag, K.G. Postmenopausal osteoporosis: what have we learned since the introduction of bisphosphonates? Rev Endocr Metab Disord 2006, 7(1-2), 101-112.
32. Delaney, M.F. Strategies for the prevention and treatment of osteoporosis during early postmenopause. Am J Obstet Gynecol 2006, 194(Suppl 2), S12-S23.
33. Rogers, A.; Saleh, G.; Hannon, R.A.; Greenfield, D.; Eastell, R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002, 87(10), 4470-4475. (Pubitemid 35247027)
34. Ettinger, B.; Pressman, A.; Sklarin, P.; Bauer, D.C.; Cauley, J.A.; Cummings, S.R. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab 1998, 83(7), 2239-2243.
35. Warming, L.; Hassager, C.; Christiansen, C. Changes in bone mineral density with age in men and women: A longitudinal study. Osteoporos Int 2002, 13(2), 105-112.
36. Kanis, J.A.; Delmas, P.; Burckhardt, P.; Cooper, C.; Torgerson, D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997, 7(4), 390-406.
37. Kanis, J.A.; McCloskey, E.V.; Powles, T.; Paterson, A.H.; Ashley, S.; Spector, T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999, 79(7-8), 1179-1181.
38. Rugo, H.S. The breast cancer continuum in hormone-receptorpositive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol 2008, 19(1), 16-27.
39. Conte, P.; Frassoldati, A. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: putting safety into perspective. Breast J 2007, 13(1), 28-35.
40. Eastell, R.; Hannon, R.A.; Cuzick, J.; Dowsett, M.; Clack, G.; Adams, J.E.; ATAC Trialists' group. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrazole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230). J Bone Mineral Res 2006, 21(8), 1215-1223.
41. Ramaswamy, B.; Shapiro, C.L. Osteopenia and osteoporosis in women with breast cancer. Semin Oncol 2003, 30(6), 763-775.
42. McCloskey, E.; Hannon, R.; Lakner, G.; Clack, G.; Miyamoto, A.; Eastell, R. Interaction between body mass index and bone turnover during aromatase inhibition: evidence from the letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial. J Clin Oncol 2007, 25(18S), 17S. Abstract 560.
43. McCaig, F.M.; Renshaw, L.; Williams, L.; Young, O.; Murray, J.; Macaskill, E.J.; McHugh, M.; Hannon, R.; Dixon, J. A randomised study of the effects of anastrozole (A), letrozole (L) and exemestane (E) on bone turnover. Cancer Res 2009, 69(Suppl 2), 148s-149s. Abstract 1145.
44. Goss, P.E.; Ingle, J.N.; Martino, S.; Robert, N.J.; Muss, H.B.; Piccart, M.J.; Castiglione, M.; Tu, D.; Shepherd, L.E.; Pritchard, K.I.; Livingston, R.B.; Davidson, N.E.; Norton, L.; Perez, E.A.; Abrams, J.S.; Cameron, D.A.; Palmer, M.J.; Pater, J.L. Randomised trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005, 97(17), 1262-1271.
45. Thürlimann, B; BIG 1-98 Collaborative Group. Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer. Update of the BIG 1-98 primary core analysis. 11th International St. Gallen Oncology Conferences: Primary Therapy of Early Breast Cancer; March 11-14, 2009; St. Gallen, Switzerland. Abstract 0161.
46. Jones, S.E.; Seynaeve, C.; Hasenburg, A.; Rae, D.; Vannetzel, JM; Paridaens, R.; Markopoulos, C.; Hozumi, Y.; Putter, H.; Hille, E.; Kieback, D.; Asmar, L.; Smeets, J.; Urbanski, R.; Bartlett, M.J.S.; van de Velde, C.J.H. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Res 2009, 69(Suppl 2), 67s. Abstract 15.
47. Jakesz, R.; Jonat,W.; Gnant,M.; Mittlboeck, M.; Greil, R.; Tausch, C.; Hilfrich, J.; Kwasny, W.; Menzel, C.; Samonigg, H.; Seifert, M.; Gademann, G.; Kaufmann, M.; Wolfgang J; ABCSG and the GABG. Switching of postmenopausal women with endocrineresponsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 366(9484), 455-462.
48. Hadji, P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 2009, 69(1), 73-82.
49. Hadji, P.; Body, J.J.; Aapro, M.S.; Brufsky, A.; Coleman, R.E.; Guise, T.; Lipton, A.; Tubiana-Hulin, M. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008, 19(8), 1407-1416.
50. FRAX: Fracture Risk Assessment Tool FRAX. Available at: http://www.shef.ac.uk/FRAX/. Accessed October 6, 2009.
51. Hillner, B.E.; Ingle, J.N.; Chlebowski, R.T.; Gralow, J.; Yee, G.C.; Janjan, N.A.; Cauley, J.A.; Blumenstein, B.A.; Albain, K.S.; Lipton, A.; Brown, S.; American Society of Clinical Oncology. American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21(21), 4042-4057.
52. Thorne, C. Clinical management of arthralgia and bone health in women undergoing adjuvant aromatase inhibitor therapy. Curr Opin Oncol 2007, 19(Suppl 1), S19-S28.
53. Brufsky, A.; Dong, M.; Lund, K.; Warsi, G.; Cobb, P.; Eisenberg, P.; Papish, S.; Lacerna, L.; Perez, E. Twenty-four month followup of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). Breast Cancer Res Treat 2006, 100(Suppl 1), S233. Abstract 5060.
54. Aapro, M.; Hadji, P.; Brufsky, A.; Tubiana-Hulin, M.; Guise, T.; Body, J.J. Recommendations for the prevention of aromatase inhibitor-associated bone loss in women with breast cancer. Eur J Cancer 2007, 5(Suppl 5), 186. Abstract 2007.
55. Reid, D.M.; Doughty, J.; Eastell, R.; Heys, S.D.; Howell, A.; McCloskey, E.V.; Powles, T.; Selby, P.; Coleman, R.E. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008, 34(Suppl 1), S3-S18.
56. Brufsky, A.; Harker,W.; Beck, J.; Carroll, R.; Tan-Chiu, E.; Seidler, C.; Lacerna, L.; Thomas, E.; Perez, E.; The Z-FAST Study Group. Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PWM) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial. J Clin Oncol 2005, 23(16s), 12s. Abstract 533.
57. Pal, S.K.; Mortimer, J. Adjuvant systemic therapy for older adults with early-stage breast cancer. Womens Health (Lond Engl) 2009, 5(3), 251-262.
58. Drake, M.T.; Clarke, B.L.; Khosla, S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008, 83(9), 1032-1045.
59. Coleman, R.E. Bisphosphonates: clinical experience. Oncologist. 2004, 9(Suppl 4), 14-27.
60. Brufsky, A.; Harker, W.G.; Beck, J.T.; Carroll, R.; Tan-Chiu, E.; Seidler, C.; Hohneker, J.; Lacerna, L.; Petrone, S.; Perez, E.A. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007, 25(7), 829-836.
61. Bundred, N.J.; Campbell, I.D.; Davidson, N.; DeBoer, R.H.; Eidtmann, H.; Monnier, A.; Neven, P.; von Minckwitz, G.; Miller, J.C.; Schenk, N.L.; Coleman, R.E. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008, 112(5), 1001-1010.
62. Brufsky, A.; Bosserman, L.; Caradonna, R.; Haley, B.; Jones, M.; Moore, H.; Dong, M.; Warsi, G.; Lacerna, L.; Perez, E.. Z-FAST Study Group. The effect of zoledronic acid on aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up. Breast Cancer Res Treat 2007, 106(Suppl 1), S8. Abstract 27.
63. Eidtmann, H.; Bundred, N.J.; DeBoer, R.; Llombart, A.; Davidson, N.; Neven, P.; von Minckwitz, G.; Miller, J.; Schenk, N.; Coleman, R. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Cancer Res 2009, 69(Suppl 2), 74s. Abstract 44.
64. Llombart-Cussac, A. Zoledronic acid in the prevention of aromatase inhibitor-associated bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (EZO- FAST Trial). 14th European Cancer Conference (ECCO 14); September 23-27, 2007; Barcelona, Spain. Abstract 2.044.
65. Gnant,M.F.; Mlineritsch, B.; Luschin-Ebengreuth, G.;Grampp, S.; Kaessmann, H.; Schmid, M.; Menzel, C.; Piswanger-Soelkner, J.C.; Galid, A.; Mittlboeck, M.; Hausmaninger, H.; Jakesz, R.; Austrian Breast and Colorectal Cancer Study Group. Zoledronic Acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25(7), 820-828.
66. Gnant, M.; Mlineritsch, B.; Luschin-Ebengreuth, G.; Kainberger, F.; Kaessmann, H.; Piswanger-Soelkner, C.; Seifert, M.; Schippinger, W.; Menzel, C.; Dubsky, P.; Fitzal, F.; Steger, G.; Greil, R.; Marth, C.; Kubista, E.; Samonigg, H.; Jakesz, R. Bone mineral density (BMD) at 5 years after diagnosis in premenopausal patients with endocrine-responsive breast cancer, after 3 years of adjuvant endocrine treatment with goserelin and tamoxifen or anastrozole or both treatments in combination with zoledronic acid - new results from ABCSG-12. Breast Cancer Res Treat 2007, 106(Suppl 1), S8. Abstract 26.
67. Gnant, M.; Mlineritsch, B.; Luschin-Ebengreuth, G.; Kainberger, F.; Kassmann, H.; Piswanger-Solkner, J.C.; Seifert, M.; Ploner, F.; Menzel, C.; Dubsky, P.; Fitzal, F.; Bjelic- Radisic, V.; Steger, G.; Greil, R.; Marth, C.; Kubista, E.; Samonigg, H.; Wohlmuth, P.; Mittlbock, M.; Jakesz, R.; Austrian, Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008, 9(9), 840-849.
68. Lester, J.; Dodwell, D.; Purohit, O.P.; Gutcher, S.A.; Ellis, S.P.; Thorpe, R.; Horsman, J.M.; Brown, J.E.; Hannon, R.A.; Coleman, R.E. Use of monthly oral ibandronate to prevent anastrozoleinduced bone loss during adjuvant treatment for breast cancer: two-year results from the ARIBON study. J Clin Oncol 2008, 26(15s), 19s. Abstract 554.
69. Lester, J.E.; Dodwell, D.; Purohit, O.P.; Gutcher, S.A.; Ellis, S.P.; Thorpe, R.; Horsman, J.M.; Brown, J.E.; Hannon, R.A.; Coleman, R.E. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008, 14(19), 6336-6342.
70. Hines, S.L.; Mincey, B.A.; Sloan, J.A.; Thomas, S.P.; Chottiner, E.; Loprinzi, C.L.; Carlson, M.D.; Atherton, P.J.; Salim, M.; Perez, E.A. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 2009, 27(7), 1047-1053.
71. Hines, S.L.; Mincey, B.A.; Sloan, J.A.; Thomas, S.P.; Chotttiner, E.G.; Loprinzi, C.L.; Atherton, P.J.; Carlson, M.D.; Salim, M.; Perez, E.A. NO2C1: A phase III randomized, placebo-controlled, double-blind trial of risedronate for prevention of bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer (BC). J Clin Oncol 2008, 26(15s), 12s. Abstract 525.
72. Van Poznak, C.; Hannon, R.A.; Clack, G.; Campone, M.; Mackey, J.R.; Apffelstaedt, J.; Eastell, R. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis. Breast Cancer Res Treat. 2007, 106(Suppl 1), S37. Abstract 502.
73. Van Poznak, C.; Hannon, R.; Clack, G.; Campone, M.; Mackey, J.R.; Apffelstaedt, J.; Eastell, R., on behalf of the SABRE Investigators. Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE). Cancer Res 2009, 69(Suppl 2), 146s. Abstract 1137.
74. Ellis, G.K.; Bone, H.G.; Chlebowski, R.; Paul, D.; Spadafora, S.; Smith, J.; Fan, M.; Jun, S. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008, 26(30), 4875-4882.
75. Carteni, G.; Bordonaro, R.; Giotta, F.; Lorusso, V.; Scalone, S.; Vinaccia, V.; Rondena, R.; Amadori, D. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist 2006, 11(7), 841-848.
76. Diel, I.J.; Solomayer, E-F; Costa, S.D.; Gollan, C.; Goerner, R.; Wallwiener, D.; Kaufmann, M.; Bastert, G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339(6), 357-363.
77. Diel, I.; Solomayer, E.-F.; Gollan, Ch.; Schutz, F.; Bastert, G. Bisphosphonates in the reduction of metastases in breast cancer-results of the extended follow-up of the first study population. Proc Am Soc Clin Oncol 2000, 19. Abstract 314.
78. Jaschke, A.; Bastert, G.; Solomayer, E.F.; Costa, S.; Schuetz, F.; Diel, I.J. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - a longtime follow-up. Proc Am Soc Clin Oncol 2004, 23, 9. Abstract 529.
79. Powles, T.; Paterson, S.; Kanis, J.A.; McCloskey, E.; Ashley, S.; Tidy, A.; Rosenqvist, K.; Smith, I.; Ottestad, L.; Legault, S.; Pajunen, M.; Nevantaus, A.; Männistö, E.; Suovuori, A.; Atula, S.; Nevalainen, J.; Pylkkänen, L. Randomized placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002, 20(15), 3219-3224.
80. Powles, T.J.; Paterson, A.; McCloskey, E.; Schein, P.; Scheffler, B.; Tidy, A.; Ashley, S.; Smith, I.; Ottestad, L.; Kanis, J. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 2006, 8(2), R13.
81. Saarto, T.; Vehmanen, L.; Virkkunen, P.; Blomqvist, C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004, 43(7), 650-656.
82. Paterson, A.H.G.; Powles, T.J.; Kanis, J.A.; McCloskey, E.; Hanson, J.; Ashley, S.E. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11(1), 59-65.
83. Kristensen, B.; Ejlertsen, B.; Mouridsen, H.T.; Jensen, M.B.; Andersen, J.; Bjerregaard, B.; Cold, S.; Edlund, P.; Ewertz, M.; Kamby, C.; Lindman, H.; Norenskjold, B.; Bergh, J. Bisphosphonate treatment in primary breast cancer: results from a randomized comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008, 47(4), 740-746.
84. Gnant, M. The evolving role of zoledronic acid in early breast cancer. OncoTargets Therapy 2009, 2, 95-104.
85. Gnant, M.; Mlineritsch, B.; Schippinger, W.; Luschin-Ebengreuth, G.; Pöstlberger, S.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Bjelic-Radisic, V.; Samonigg, H.; Tausch, C.; Eidtmann, H.; Steger, G.; Kwasny, W.; Dubsky, P.; Fridrik, M.; Fitzal, F.; Stierer, M.; Rücklinger, E.; Greil R; ABCSG-12 Trial Investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360(7), 679-691. Erratum in: N Engl J Med 2009;28;360(22):2379.
86. Mystakidou, K.; Katsouda, E.; Parpa, E.; Kelekis, A.; Galanos, A.; Vlahos, L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005, 22(2), 195-201.
87. Avil ́ es, A.; Nambo, M.J.; Neri, N.; Castañeda, C.; Cleto, S.; Huerta-Guzḿan, J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007, 24(2), 227-230.
88. Zaghloul, M.S.; Boutrus, R.; El-Hosieny, H.; A-Kader, Y.; El- Attar, I.; Nazmy,M. A controlled prospective randomized placebocontrolled trial of zoledronic acid in bony metastatic bladder cancer patients. J Clin Oncol 2008, 26(15S), 257s. Abstract 5033.
89. Zaghloul, M.S.; Khaled, H.M.; Lotayef, M.; William, H. Adjuvant chemoradiotherapy after radical cystectomy in advanced high risk bladder cancer: A prospective randomized trial. J Clin Oncol 2006, 24(18S), 227s. Abstract 4545.
90. Aft, R.;Watson, M.; Ylagan, L.; Chavez-MacGregor, M.; Trinkaus, K.; Zhai, J.; Naughton, M.; Weilbaecher, K. Effect of zoledronic acid on bone marrow micrometastases in women undergoing neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2008, 26(May 20 Suppl). Abstract 1021.
91. Rack, B.K.; Jueckstock, J.; Genss, E-M; Schoberth, A.; Schindlbeck, C.; Strobl, B.; Heinrigs, M.; Rammel, G.; Zwingers, T.; Sommer, H.; Friese, K.; Janni,W. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. Breast Cancer Res Treat 2007, 106(Suppl 1), S40. Abstract 511.
92. Lin, A.Y.; Park, J.W.; Scott, J.; Melisko, M.; Goga, A.; Moasser, M.M.; Moore, D.H.; Rugo, H.S. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. J Clin Oncol 2008, 26(15S), 20s. Abstract 559.
93. Solomayer, E.F.; Gebauer, G.; Hirnle, P.; Janni, W.; Lück, H-J; Becker, S.; Huober, J.; Kraemer, B.; Wackwitz, B.; Fehm, T. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Cancer Res 2009, 69(Suppl 2), 170s-171s. Abstract 2048.
94. Gnant, M.; Mlineritsch, B.; Schippinger, W.; Luschin-Ebengreuth, G.; Steger, G.G.; Bjelic-Radisic, V.; Jakesz, R.; Kubista, E.;Marth, C.; Greil, R. Zoledronic acid (ZOL) improves disease-free (DFS) and recurrence-free survival (RFS) in premenopausal women with early breast cancer (ERBC) receiving adjuvant endocrine therapy: multivariate analysis of efficacy data from the Austrian Breast and Colorectal Cancer Study Group (ABCSG)-12. Presented at the 33rd Annual Congress of the European Society of Medical Oncology (ESMO). Ann Oncol 2008, 19(Suppl 8), viii44. Abstract 69O.
95. Frassoldati, A.; Brufsky, A.; Bundred, N.; Lambert-Falls, R.; Hadji, P.; Mena, R.; Paia, O.; Coleman, R. The effect of zoledronic acid on aromatase inhibitor (AI) associated bone loss (AIBL) in postmenopausal women (PMV) with early breast cancer (EBC) receiving adjuvant Letrozole: 24 months (MOS) integrated followup of the Z-FAST/ZO-FAST trials. Ann Oncol 2008, 19(Suppl 8), viii78. Abstract 185PD.
96. Winter, M.C.; Thorpe, H.C.; Burkinshaw, R.; Beevers, S.J.; Coleman, R.E. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response - exploratory evidence for direct anti-tumor activity in breast cancer. Cancer Res 2009, 69(Suppl 2), 338s-339s. Abstract 5101.
97. Garreau, J.R.; Delamelena, T.; Walts, D.; Karamlou, K.; Johnson, N. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. Am J Surg 2006, 192(4): 496-498.
98. Crew, K.D.; Greenlee, H.; Capodice, J.; Raptis, G.; Brafman, L.; Fuentes, D.; Sierra, A.; Hershman, D.L. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007, 25(25), 3877-3883.
99. Burstein, H.J. Aromatase inhibitor-associated arthralgia syndrome. Breast 2007, 16(3), 223-234.
100. Coleman, R.E.; Bolten, W.W.; Lansdown, M.; Dale, S.; Jackisch, C.; Merkel, D.; Maass, N.; Hadji, P. Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations. Cancer Treat Rev 2007, 34(3), 275-282.
101. Felson, D.T.; Cummings, S.R. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 2005, 52(9), 2594-2598.
102. Donnellan, P.P.; Douglas, S.L.; Cameron, D.A.; Leonard, R.C. Aromatase inhibitors and arthralgias. J Clin Oncol 2001, 19(10), 2767.
103. Mackey, J.; Gelmon, K. Adjuvant aromatase inhibitors in breast cancer therapy: significance of musculoskeletal complications. Curr Opin Oncol 2007, 10(Suppl 1), S9-S18.
104. Cuzick, J.; Sestak, I.; Cella, D.; Fallowfield, L; ATAC Trialists' Group. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 2008, 9(12), 1143-1148.
105. Buzdar, A.U., on behalf of the ATAC Trialists' Group. Clinical features of joint symptoms observed in the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 2006, 24(18S), 15s. Abstract 551.
106. Renshaw, L.; McHugh, M.; Williams, L., et al. Comparison of joint problems as reported by patients in a randomized adjuvant trial of anastrozole and letrozole. Breast Cancer Res Treat 2007, 106(Suppl 1), S108-S109. Abstract 2072.
107. Briot, K.; Bastit, L.; Rotarsky, M.; Spaeth, D.; Tubiana, M.; Mauresan Kloos, I.; Bourdeix, I.; Roux, C. Effects of switching aromatase inhibitors on arthralgia: the ATOLL study. Cancer Res 2009, 69(Suppl 2), 147s-148s. Abstract 1142.
108. Howell, A.; Cuzick, J. Vascular effects of aromatase inhibitors: data from clinical trials. J Steroid Biochem Mol Biol 2005, 95(1-5), 143-149.
109. Stearns, V.; Johnson, M.D.; Rae, J.M.; Morocho, A.; Novielli, A.; Bhargava, P.; Hayes, D.F.; Desta, Z.; Flockhart, D.A. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003, 95(23), 1758-1764.
110. Biglia, N.; Torta, R.; Roagna, R.; Maggiorotto, F.; Cacciari, F.; Ponzone, R.; Kubatzki, F.; Sismondi, P. Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas 2005, 52(1), 78-85.
111. Goldberg, R.M.; Loprinzi, C.L.; O'Fallan, J.R.; Veeder, M.H.; Miser, A.W.; Mailliard, J.A.; Michalak, J.C.; Dose, A.M.; Rowland, K.M. Jr, Burnham, N.L. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994, 12(1), 155-158. Erratum in: J Clin Oncol 1996 Aug;14(8):2411.
112. Loprinzi, C.L.; Michalak, J.C.; Quella, S.K.; O'Fallen, J.R.; Hatfield, A.K.; Nelimark, R.A.; Dose, A.M.; Fischer, T.; Johnson, C.; Klatt, N.E.; Bate,W.W.; Rospond, R.M.;Oesterling, J.E. Megestrol acetate for the prevention of hot flashes. N Eng J Med 1994, 331(6), 347-352.
113. Loprinzi, C.L.; Barton, D.L.; Sloan, J.A.; Novotny, P.J.; Dakhil, S.R.; Verdirame, J.D.; Knutson, W.H.; Kelaghan, J.; Christensen, B. Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience. Menopause 2008, 15(4 Pt 1), 655-660.
114. Harris, P.F.; Remington, P.L.; Trentham-Dietz, A.; Allen, C.I.; Newcomb, P.A. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 2002, 23(6), 501-509.
115. Deng, G.; Vickers, A.J.; Yeung, S.; D'Andrea, G.M.; Xiao, H.; Heerdt, A.S.; Sugarman, S.; Troso-Sandoval, T.; Seidman, A.D.; Hudis, C.A.; Cassileth, B. Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. J Clin Oncol 2007, 25(35), 5584-5590.
116. Quella, S.K.; Loprinzi, C.L.; Barton, D.L.; Knost, J.A.; Sloan, J.A.; LaVasseur, B.I.; Swan, D.; Krupp, K.R.; Miller, K.D.; Novotny, P.J. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 2000, 18(5), 1068-1074.
117. Ju, Y.H.; Doerge, D.R.; Woodling, K.A.; Hartman, J.A.; Kwak, J.; Helferich, W.G. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogendependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis 2008, 29(11), 2162-2168.
118. Burkhart, P.V.; Sabat́ e, E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh 2003, 35(3), 207.
119. World Health Organization. 2003 Adherence to long-term therapies: evidence for action. Geneva, Switzerland. Available at: http://apps.who.int/ medicinedocs/en/d/Js4883e/. Accessed May 26, 2010.
120. Sullivan, S.D.; Kreling, D.H.; Hazlet, T.K. Noncompliance with medication regimens and subsequent hospitalizations: a literature analysis and cost of hospitalization estimate. J Research Pharm Econ 1990, 2(2), 19-33.
121. Baum, M.; Budzar, A.U.; Cuzick, J.; Forbes, J.; Houghton, J.H.; Klijn, J.G.; Sahmoud T; ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359(9324), 2131-2139. Erratum in: Lancet 2002;360(9344):1520.
122. Houghton, J., on behalf of the ATAC Trialists' Group. Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: updated data from the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial. J Clin Oncol 2005, 23(16S), 24s. Abstract 582.
123. Houghton, J., on behalf of the ATAC Trialists' Group. Initial adjuvant
124. Partridge, A.H.; LaFountain, A.; Mayer, E.; Taylor, B.S.; Winer, E.; Asnis-Alibozek, A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008, 26(4), 556-562.
125. Wengström, Y. Patients need to know. Eur J Cancer 2006, 42(18), 3083.
126. Osterberg, L.; Blaschke, T. Adherence to medication. N Engl J Med 2005, 353(5), 487-497.
127. Davidson, B.; Vogel, V.; Wickerham, L. Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy. J Support Oncol 2007, 5(3), 139-143.
128. Wengström, Y.; Aapro, M.; Leto di Priolo, S.; Cannon, H.; Georgiou, V. Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study. Breast 2007, 16(5), 462-468.
129. McCowan, C.; Shearer, J.; Donnan, P.T.; Dewar, J.A.; Crilly, M.; Thompson, A.M.; Fahey, T.P. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008, 99(11), 1763-1768.
130. Wildiers, H.; Kunkler, I.; Biganzoli, L.; Fracheboud, J.; Vlastos, G.; Bernard-Marty, C.; Hurria, A.; Extermann, M.; Girre, V.; Brain, E.; Audisio, R.A.; Bartelink, H.; Barton, M.; Giordano, S.H.; Muss, H.; Aapro, M.; International Society of Geriatric Oncology. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007, 8(12), 1101-1115. (Pubitemid 350182967)
131. Santini, D.; Fratto, M.E.; Galluzzo, S.; Vincenzi, B.; Tonini, G. Are bisphosphonates the suitable anticancer drugs for the elderly? Crit Rev Oncol Hematol 2009, 69(1), 83-94.
132. Aapro, M.; Crivellari, D. The use of adjuvant endocrine therapy in older women with estrogen receptor-positive (ER+) breast cancer (BC). Ann Oncol 2008, 19(Suppl 8), viii8-viii9. Abstract 655P.
133. Lichtman, S.M.; Wildiers, H.; Chatelut, E.; Steer, C.; Budman, D.; Morrison, V.A.; Tranchand, B.; Shapira, I.; Aapro, M.; International Society of Geriatric Oncology Chemotherapy Taskforce. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients-an analysis of the medical literature. J Clin Oncol 2007, 25(14), 1832-1843.
134. Body, J.J.; Coleman, R.; Clezardin, P.; Ripamonti, C.; Rizzoli, R.; Aapro, M.; International Society of Geriatric Oncology. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 2007, 43(5), 852-858. (Pubitemid 46366687)
135. Crivellari, D.; Sun, Z.; Coates, A.S.; Price, K.N.; Thürlimann, B.; Mouridsen, H.; Mauriac, L.; Forbes, J.F.; Paridaens, R.J.; Castiglione-Gertsch, M.; Gelber, R.D.; Colleoni, M.; Ĺang, I.; Del Mastro, L.; Gladieff, L.; Rabaglio, M.; Smith, I.E.; Chirgwin, J.H.; Goldhirsch, A. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 2008, 26(12), 1972-1979.
136. Muss, H.B.; Tu, D.; Ingle, J.N.; Martino, S.; Robert, N.J.; Pater, J.L.; Whelan, T.; Palmer, M.J.; Piccart, M.J.; Shepherd, L.E.; Pritchard, K.I.; He, Z.; Goss, P.E. The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age. Breast Cancer Res Treat 2006, 100(Suppl 1), S23. Abstract 102.
137. Chapman, J.W.; Meng, D.; Shephardm, L.; Parulekar, W.; Ingle, J.N.; Muss, H.B.; Palmer, M.; Yu, C.; Goss, P.E. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 2008, 100(4), 252-260.